Eupraxia Pharmaceuticals (EPRX) Restructuring Costs (2024 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Restructuring Costs of $1.9 million for Q1 2026, up 34.94% year-over-year from $1.4 million in Q1 2025, and up 30.54% quarter-over-quarter from $1.5 million in Q3 2025.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Restructuring Costs (2024 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Restructuring Costs for 3 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Eupraxia Pharmaceuticals | 317.25 Mn | 317.25 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.43 Mn |
| Mar 31, 2026 | 1.94 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Jun 30, 2025 | 1.59 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.84 Mn |